Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.83 USD | -5.01% | +2.41% | +63.25% |
May. 10 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
May. 09 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.25% | 1.75B | |
+42.32% | 54.04B | |
+43.57% | 41.96B | |
-1.26% | 41.92B | |
-7.59% | 28.35B | |
+11.71% | 26.35B | |
-22.30% | 19B | |
+7.87% | 13B | |
+28.88% | 12.28B | |
+25.47% | 12.19B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- RBC Initiates Edgewise Therapeutics at Outperform, Speculative Risk With $31 Price Target, Bullish on '5506 Treatment for Muscular Dystrophies